Hope for Long-Term muscle disease control
NCT ID NCT06926621
Summary
This study aims to learn about the long-term safety and effects of the drug VX-670 in adults with myotonic dystrophy type 1 (DM1). It is an extension study for 44 people who have already completed a previous trial with this drug. The main goal is to monitor participants for side effects and see how their bodies process the medication over a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences Montreal
Montreal, Canada
-
Hospital Universitario y Politecnico La Fe - Neurology
Valencia, Spain
-
Leonard Wolfson Experimental Neurology Centre CRF
London, United Kingdom
-
Montreal Neurological Institute-Hospital
Montreal, Canada
-
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, Australia
-
Queen Elizabeth University Hospital - Neurology
Glasgow, United Kingdom
-
Royal Hallamshire Hospital - Neurology
Sheffield, United Kingdom
-
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
Leuven, Belgium
-
Universite Laval - Neurology
Québec, Canada
-
University of Ottawa
Ottawa, Canada
-
Wesley Research Institute
Auchenflower, Australia
Conditions
Explore the condition pages connected to this study.